The period for CME/CE credit for this activity has expired.

Diabetes

Peak Issues: Clinical Use Of Incretin-Based Therapies To Promote PPG Control In Type 2 Diabetes

INSTRUCTIONS

After completing the demographic questionnaire and the CME posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


CME/CE Information
TERM OF APPROVAL
Release date: April 2009
Expiration date: April 30, 2010

PROGRAM OVERVIEW
Several landmark clinical studies have demonstrated the relationship
between type 2 diabetes and increased risk of both microvascular
and macrovascular complications. Optimal glycemic control is vital
to managing these risks in patients with type 2 diabetes. However,
recent estimates indicate that only 57% of type 2 diabetes patients
reach the American Diabetes Association glycemic target of A1C < 7%.

Historically, glycemic control efforts have emphasized achievement of A1C and fasting plasma glucose (FPG) targets. It has recently become increasingly evident that postprandial increases in blood glucose levels also contribute significantly to overall glycemic control and to the development of diabetes complications. Consequently, postprandial plasma glucose (PPG) control is receiving recognition as an essential therapeutic target for optimizing glycemic control in patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.

INTENDED AUDIENCE
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes.

LEARNING OBJECTIVES
After completing this issue, participants should be able to:

• Describe the relative contribution of FPG and PPG to overall glycemic control among patients with type 2 diabetes, and explain how this relationship changes at different levels of glycemic control

• Explain the pathophysiologic defects that precede the development of type 2 diabetes, and indicate when elevated PPG begins to play a contributing role

• Discuss the available evidence suggesting that elevated PPG leads to increased macrovascular complications

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

IMNE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURES
In compliance with the ACCME’s Standards for Commercial Support, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in
planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label or investigational use of pharmaceutical agents and medical devices.

In accordance with ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content. The following disclosures have been made:

FACULTY
David D’Alessio, MD
Formal Advisor: Takeda Pharmaceuticals North America, Inc;
Merck & Co, Inc
Research Activities: Amylin Pharmaceuticals, Inc; Eli Lilly and Company; ETHICON, Inc
Consultant: Amylin Pharmaceuticals, Inc; MannKind Corporation

CME AND EDUCATIONAL PARTNER STAFF
Steve Weinman, RN
Executive Director
IMNE
Disclosures: Nothing to disclose

Amy Groves
Director, Program Development
IMNE
Disclosures: Nothing to disclose

Katie Fidanza
Program Development Executive
IMNE
Disclosures: Nothing to disclose

Kim McFarland, PhD
Senior Medical Writer
IMNE
Freelance Writer: MediTech Media, Ltd
Stock Interests: Pfizer Inc; Procter & Gamble

Robert Hash, MD
Texas A&M Health Science Center
College of Medicine
College Station, Texas
Dr Hash has nothing to disclose.

Martin Quan, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Dr Quan has nothing to disclose.

DISCLAIMER
This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

Takeda Pharmaceuticals North America
This activity is partially supported by an educational grant from Takeda
Pharmaceuticals North America, Inc.

METHOD OF OBTAINING CME CREDIT
CME credit/verification is offered upon successful completion of a posttest with a minimum passing score of 70%. CME certificates will be issued to participants after receipt of the CME registration form, evaluation form, and successfully completed posttest. For those taking the test and completing the evaluation online at www.webbasedCME.com, a printable certificate will be made available upon successful completion of the posttest.

Questions or comments can be addressed to steve.weinman@imne.com.

If you choose to apply for CME credit by mail or fax, please allow up to 12 weeks for issuance of CME credit.

 I have read and understand the CME Information indexed above.

    •  
    • PPG-Issue-1 GraphicClick here to view the activity (.pdf)
    •  
    • Demographic Questionnaire - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • CME Posttest and Evaluation - This should be completed after the demographic questionnaire.

    You can click on each section to preview this activity but you must be signed in to participate and receive CME credit. New to WebBasedCME.com? Click here to register.